Here is a summary of major cancer-related news in June 2025. The cancer treatment landscape has changed rapidly every month, and Patient Savvy will keep you updated
✅ FDA Approvals
🗓️ June 12 – Mitomycin intravesical (Zusduri) | Company: UroGen Pharma
Indication: Non-muscle invasive bladder cancer
Zusduri is the first drug approved to treat a type of bladder cancer that hasn’t spread into muscle but keeps coming back after surgery. This new treatment is given directly into the bladder and may help patients avoid repeated surgeries, which can be risky, especially for older adults.
Source: Urology Times
🗓️ June 23 – Datopotamab deruxtecan (Datroway) | Company: AstraZeneca and Daiichi Sankyo
Indication: Advanced non-small cell lung cancer (EGFR-mutated)
The FDA granted fast-track approval to Datroway for patients with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation and who have already tried other treatments. This drug works by delivering chemotherapy directly to cancer cells and is intended for use when other options are no longer effective.
Source: FDA
🗓️ June 30 – Doxorubicin Hydrochloride Liposome (Generic) | Company: Alembic Pharmaceuticals
Indication: Multiple, including breast and ovarian cancer
A generic version of a commonly used cancer drug was approved, making it more affordable for patients. This drug treats several types of cancer by slowing or stopping the growth of cancer cells.
Source: Economic Times
📊 Clinical Trial Results
🗓️ June 1 – Atezolizumab (ATOMIC trial) | Company: Genentech / Roche
Indication: Stage III dMMR colon cancer
A new study found that adding atezolizumab (an immunotherapy) to chemotherapy helped reduce the chance of cancer coming back in people with a certain genetic type of colon cancer. This could become a new standard for these patients.
Source: ASCO
🗓️ June 2 – Onvansertib + Paclitaxel | Company: Cardiff Oncology
Indication: Metastatic triple-negative breast cancer
Early results showed that combining onvansertib with standard chemotherapy helped shrink tumors in patients with aggressive breast cancer that has spread. The treatment was generally well tolerated.
Source: GlobeNewswire
🗓️ June 16 – Ibrutinib + Venetoclax (FLAIR trial) | Organization: UK Research Team
Indication: Chronic lymphocytic leukemia (CLL)
In a long-term study, nearly all patients (94%) treated with this pill combination were still alive and without disease progression after five years. It may replace older chemotherapy approaches for this slow-growing blood cancer.
Source: The Guardian
🗓️ June 30 – Bemarituzumab (FORTITUDE-101 trial) | Company: Amgen
Indication: FGFR2b-positive advanced gastric cancer
Patients with advanced stomach cancer whose tumors had a certain protein (FGFR2b) lived longer when given this targeted therapy alongside chemotherapy. It offers new hope for a group with few options.
Source: Reuters
🔬 Research & Innovation
🗓️ June 6 – Exercise and Cancer Outcomes | Institution: Queen’s University, Canada
Topic: Colon cancer survival
A long-term study showed that regular exercise after colon cancer diagnosis helped people live longer and lowered the risk of cancer returning. This supports making physical activity part of treatment plans.
Source: The Guardian
🗓️ June 7 – Breast Cancer Vaccine (Phase 1 trial) | Organizations: Anixa Biosciences & Cleveland Clinic
Topic: Prevention of triple-negative breast cancer
A vaccine in early testing helped over 75% of participants build immunity against triple-negative breast cancer, the most difficult-to-treat type. It may eventually prevent this cancer in high-risk women.
Source: NY Post
🗓️ July 1 – Chemotherapy-Induced Blood Aging Study | Institutions: Wellcome Sanger Institute & Cambridge University
Topic: Side effects of chemotherapy
Research found that some chemotherapy drugs damage healthy blood cells, making them “age” faster. This may explain long-term fatigue and complications for cancer survivors, especially older patients.
Source: Financial Times
SIGN UP BELOW to get the latest cancer updates each month! Your inbox is safe with our strict no-spam policy
